Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
42
SXTP Quote, Financials, Valuation and Earnings
Last price:
$5.10
Seasonality move
:
-46.57%
Day range:
$3.34 - $5.19
52-week range:
$1.36 - $24.00
Dividend yield:
0%
P/E ratio:
15.22x
P/S ratio:
2.42x
P/B ratio:
--
Volume:
1.8M
Avg. volume:
6.8M
1-year change:
-72.94%
Market cap:
$6.2M
Revenue:
$681.3K
EPS (TTM):
-$7.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$535K | -$2.00 | 104.67% | -87% | $4.40 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.13% | 55.33% | $136.47 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -- | -- | -- | $47.50 |
|
MRNA
Moderna, Inc.
|
$620M | -$2.73 | 153.3% | -6.5% | $37.70 |
|
PCSA
Processa Pharmaceuticals, Inc.
|
-- | -$1.50 | -- | -92.26% | $1.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$4.84 | $4.40 | $6.2M | 15.22x | $0.00 | 0% | 2.42x |
|
ABT
Abbott Laboratories
|
$108.77 | $136.47 | $189.1B | 29.37x | $0.63 | 2.21% | 4.29x |
|
CVM
CEL-SCI Corp.
|
$6.18 | $42.50 | $18.8M | -- | $0.00 | 0% | -- |
|
GLSI
Greenwich LifeSciences, Inc.
|
$30.62 | $47.50 | $424.2M | -- | $0.00 | 0% | -- |
|
MRNA
Moderna, Inc.
|
$47.99 | $37.70 | $18.8B | -- | $0.00 | 0% | 8.33x |
|
PCSA
Processa Pharmaceuticals, Inc.
|
$3.13 | $1.00 | $7.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
3.36% | -0.088 | 1.32% | 2.18x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | -- | 1.12x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -0.588 | -- | 2.35x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.833 | 7.28% | 3.30x |
|
PCSA
Processa Pharmaceuticals, Inc.
|
-- | 4.201 | -- | 3.60x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
-$9.1K | -$2.3M | -186.16% | -193.16% | -439.94% | -$2.1M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -$4.2M | -781.94% | -781.94% | -- | -$2.7M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
PCSA
Processa Pharmaceuticals, Inc.
|
-$300 | -$3.5M | -306.05% | -309.65% | -- | -$3.5M |
60 Degrees Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SXTP or ABT?
Abbott Laboratories has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of 15.5%. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $4.40, signalling upside risk potential of 263.64%. On the other hand Abbott Laboratories has an analysts' consensus of $136.47 which suggests that it could grow by 25.47%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Abbott Laboratories, analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 ABTAbbott Laboratories15 8 0 -
Is SXTP or ABT More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.21% to investors and pays a quarterly dividend of $0.63 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is lower than Abbott Laboratories's net income of $1.8B. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Abbott Laboratories's PE ratio is 29.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 2.42x versus 4.29x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.2.42x 15.22x $528.6K -$2.3M ABTAbbott Laboratories4.29x 29.37x $11.5B $1.8B
-
Which has Higher Returns SXTP or CVM?
CEL-SCI Corp. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of --. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About SXTP or CVM?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $4.40, signalling upside risk potential of 263.64%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 587.7%. Given that CEL-SCI Corp. has higher upside potential than 60 Degrees Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than 60 Degrees Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 CVMCEL-SCI Corp.1 0 0 -
Is SXTP or CVM More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock SXTP or CVM?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or CVM?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are larger than CEL-SCI Corp. quarterly revenues of --. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 2.42x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.2.42x 15.22x $528.6K -$2.3M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns SXTP or GLSI?
Greenwich LifeSciences, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of --. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Greenwich LifeSciences, Inc.'s return on equity of -781.94%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M -
What do Analysts Say About SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $4.40, signalling upside risk potential of 263.64%. On the other hand Greenwich LifeSciences, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 55.13%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 GLSIGreenwich LifeSciences, Inc.2 0 0 -
Is SXTP or GLSI More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Greenwich LifeSciences, Inc. has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.943%.
-
Which is a Better Dividend Stock SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Greenwich LifeSciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Greenwich LifeSciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are larger than Greenwich LifeSciences, Inc. quarterly revenues of --. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Greenwich LifeSciences, Inc.'s net income of -$4.2M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Greenwich LifeSciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 2.42x versus -- for Greenwich LifeSciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.2.42x 15.22x $528.6K -$2.3M GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M
-
Which has Higher Returns SXTP or MRNA?
Moderna, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of -19.69%. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $4.40, signalling upside risk potential of 263.64%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -21.44%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 MRNAModerna, Inc.2 18 1 -
Is SXTP or MRNA More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.
-
Which is a Better Dividend Stock SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are smaller than Moderna, Inc. quarterly revenues of $1B. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Moderna, Inc.'s net income of -$200M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 2.42x versus 8.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.2.42x 15.22x $528.6K -$2.3M MRNAModerna, Inc.8.33x -- $1B -$200M
-
Which has Higher Returns SXTP or PCSA?
Processa Pharmaceuticals, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of --. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Processa Pharmaceuticals, Inc.'s return on equity of -309.65%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M PCSAProcessa Pharmaceuticals, Inc.-- -$1.81 $5.8M -
What do Analysts Say About SXTP or PCSA?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $4.40, signalling upside risk potential of 263.64%. On the other hand Processa Pharmaceuticals, Inc. has an analysts' consensus of $1.00 which suggests that it could grow by 698.72%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than 60 Degrees Pharmaceuticals, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than 60 Degrees Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 PCSAProcessa Pharmaceuticals, Inc.0 1 0 -
Is SXTP or PCSA More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Processa Pharmaceuticals, Inc. has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.829%.
-
Which is a Better Dividend Stock SXTP or PCSA?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Processa Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Processa Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or PCSA?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are larger than Processa Pharmaceuticals, Inc. quarterly revenues of --. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Processa Pharmaceuticals, Inc.'s net income of -$3.4M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Processa Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 2.42x versus -- for Processa Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.2.42x 15.22x $528.6K -$2.3M PCSAProcessa Pharmaceuticals, Inc.-- -- -- -$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
73
BNAI alert for Jan 27
Brand Engagement Network, Inc. [BNAI] is up 279.19% over the past day.
Buy
71
GLSI alert for Jan 27
Greenwich LifeSciences, Inc. [GLSI] is up 19.36% over the past day.
Sell
48
RVMD alert for Jan 27
Revolution Medicines, Inc. [RVMD] is down 16.89% over the past day.
